Search
Search Results
-
DTX3L Accelerates Pancreatic cancer Progression via FAK/PI3K/AKT Axis
DTX3L (Deltex E3 ubiquitin ligase 3 L) is an E3 ubiquitin ligase, a member of the deltex family. It is also known as B-lymphoma and BAL-associated...
-
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model
BackgroundBoth modified FOLFIRINOX (mFFX) and gemcitabine/ nab -paclitaxel chemotherapy regimens have been shown to improve clinical outcomes in...
-
A Recent Overview of the Growing Applications of Biosimilars in Pancreatic Cancer Management: Current Picture and Future Perspectives
With an annual growth rate in incidence of 1.1%, high lethality and difficulties in early detection, pancreatic cancer is projected to become the...
-
FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study
BackgroundFluorouracil, leucovorin (5FU/LV), and nanoliposomal-irinotecan (nal-IRI) combination therapy has been established as the second-line...
-
Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial)
BackgroundLocally advanced pancreatic ductal adenocarcinoma (PDAC), accounting for about 30% of PDAC patients, is difficult to cure by radical...
-
Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications
BackgroundIntratumoral heterogeneity (ITH) and tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) play important roles in tumor...
-
Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
BackgroundCombination therapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) chemotherapy drastically improves survival of...
-
TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
BackgroundTargeting protein for Xenopus kinesin-like protein 2 (TPX2) overexpression in human tumours is associated with increased malignancy. Its...
-
Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer
PurposeThe distribution of tissue infiltrating lymphocytes has been shown to affect the prognosis of patients with pancreatic cancer in some previous...
-
Cancer-Derived Immunoglobulin G and Pancreatic Cancer
Immunoglobulin (Ig) is traditionally believed to be produced solely by B cells. Nonetheless, mounting evidence has demonstrated that various types of...
-
Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population
BackgroundPatients with pancreatic ductal adenocarcinoma (PDCA) carrying impaired mismatch repair mechanisms seem to have an outcome advantage under...
-
Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study
BackgroundLong-term outcomes and prognostic factors of proton radiotherapy for locally advanced pancreatic cancer (LAPC) in the body and tail are...
-
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
BackgroundThe optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the...
-
Chemokines and Chemokine Receptors in Cancer: An Update
The chemokine family is composed of small chemotactic cytokines and receptors that mediate the infiltration of various immune cells. According to the...
-
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Pancreatic cancer (PC) is a fatal disease that has a poor 5-year survival rate. The poor prognosis can be attributed to both troublesome detections...
-
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect
Pancreatic cancer has an exaggerated dependence on mitochondrial metabolism, but methods to specifically target the mitochondria without off target...
-
Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia
BackgroundPancreatic ductal adenocarcinoma (PDAC) presents with a high mortality rate. Two important features of PDAC contribute to this poor...
-
High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance
BackgroundPyroptosis, as a type of inflammatory programmed cell death, has been studied in inflammatory diseases and numerous cancers but its role in...
-
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer
BackgroundLiquid biopsy is an alternative to tissue specimens for tumour genoty**. However, the frequency of genomic alterations with low...
-
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial
PurposeChemoradiotherapy (CRT) remains the standard treatment for locally advanced rectal cancer (LARC). This phase 2 clinical trial was designed to...
